IMARC Research, a contract research organization (CRO) recently published a list of the “Top Five FDA Warning Letter Findings for Clinical Investigators.” Warning letters are issued when FDA finds objectionable conditions upon inspection. IMARC’s top 5 noted...
Please join the Circle City Chapter of Association of Clinical Research Professionals for their upcoming speaking event TOPIC: FDA Form 483’s & FDA Warning Letters Involving Clinical Drug Trials Issued in 2010: What We Can Learn Presented by David Finch, CCRP,...
Pearl IRB is pleased to launch it’s whitepaper entitled “Trends and Insights in IRB Warning Letters.” Learn all about IRB warning letters issued by the FDA, review the issues, and learn how to protect yourself from violations. Click here to...
